var data={"title":"Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Sharon Chen, PhD, MBBS, FRACP, FRCPA</a></dd><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Kieren A Marr, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Tania C Sorrell, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 17, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H3960121\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Cryptococcus gattii</em> is a fungal pathogen that is endemic in the tropics and subtropics and that has also caused an outbreak that is ongoing in British Columbia, Canada, and the United States Pacific Northwest; <em>C. gattii</em> is genetically and biochemically distinct from <em>Cryptococcus neoformans</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/1-3\" class=\"abstract_t\">1-3</a>]. Together, <em>C. gattii</em> and <em>C. neoformans</em> account for most cases of cryptococcal infections in humans, although <em>C. neoformans</em> is more common. Like <em>C. neoformans</em>, infection with <em>C. gattii</em> manifests most often as meningoencephalitis <span class=\"nowrap\">and/or</span> pneumonia.</p><p>The microbiology, epidemiology, risk factors, and pathogenesis of <em>C. gattii </em>infection will be reviewed here. The clinical features, diagnosis, and treatment of <em>C. gattii</em> infection are discussed separately. <em>C. neoformans</em> infection is also reviewed elsewhere. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Treatment&quot;</a> and <a href=\"topic.htm?path=microbiology-and-epidemiology-of-cryptococcus-neoformans-infection\" class=\"medical medical_review\">&quot;Microbiology and epidemiology of Cryptococcus neoformans infection&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3960128\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. gattii</em> is a basidiomycetous fungus, which can be found in the environment (see <a href=\"#H43972912\" class=\"local\">'Environmental exposure'</a> below). In clinical specimens, <em>C. gattii</em> is visualized as single or budding yeasts with round to cylindrical cells enveloped in a thick polysaccharide capsule. It was first proposed as a new taxonomic entity, <em>Cryptococcus neoformans </em>var<em> gattii</em>, in 1970 [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/4\" class=\"abstract_t\">4</a>], in parallel with the characterization of the capsular antigens of <em>C. neoformans</em>. It is now characterized as a separate species, <em>C. gattii</em>.</p><p>Of the four major capsular serotypes of <em>Cryptococcus</em> spp (A, B, C, and D), B and C serotypes are exclusive to what has become known as <em>C. gattii</em>, a species distinct from <em>C. neoformans</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Recognition of rare hybrids of <em>C. gattii</em> and <em>C. neoformans</em> provide evidence of taxonomic proximity, but not identity, between the two species [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p>Microbiologic tests used for the diagnosis of <em>C. gattii</em> infection are discussed separately. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H12417218\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Culture and histopathology'</a>.)</p><p class=\"headingAnchor\" id=\"H3960135\"><span class=\"h2\">Molecular types</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are at least four molecular types or genotypes of <em>C. gattii</em>, VGI to VGIV, each containing subtypes, as determined by several genotyping techniques [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/8,9\" class=\"abstract_t\">8,9</a>]. Multilocus sequence typing (MLST), based on sequences of multiple gene fragments, provides particularly reproducible and discriminatory strain differentiation and is helpful for tracking of strains in an outbreak [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/10-12\" class=\"abstract_t\">10-12</a>]. Based on these molecular types and MLST and other genotyping studies, five species within <em>C. gattii</em> have been proposed [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/13\" class=\"abstract_t\">13</a>]; however, the clinical relevance of these with respect to pathogenicity and epidemiology remains to be elucidated and hence we use the terminology &quot;<em>C.&nbsp;neoformans</em>&nbsp;species complex&quot; and &quot;<em>C.&nbsp;gattii</em>&nbsp;species complex&quot; for practical purposes, rather than creating more species [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Data from studies of molecular types of clinical (and some environmental) strains indicate that genotype distribution and frequency vary in different geographic regions (<a href=\"image.htm?imageKey=ID%2F90024\" class=\"graphic graphic_table graphicRef90024 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,15,16\" class=\"abstract_t\">3,15,16</a>]. The reasons for this are unknown but may relate to preferred ecologic niches of different genotypes. (See <a href=\"#H43972912\" class=\"local\">'Environmental exposure'</a> below.)</p><p>The following geographic distribution of genotypes has been observed [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,16\" class=\"abstract_t\">3,16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VGI is the most common genotype of isolates from Australia and Papua New Guinea, where <em>C. gattii</em> is endemic; VGII is much less common, and its occurrence appears to be geographically restricted to the &quot;Top End&quot; of the northern territory of Australia and to the southwestern region of the state of Western Australia [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,17,18\" class=\"abstract_t\">3,17,18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Isolates from the outbreak in British Columbia, Canada, and the United States Pacific Northwest are of the molecular type VGII, represented by three clonal lineages, VGIIa, VGIIb, and VGIIc [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,20\" class=\"abstract_t\">19,20</a>]. VGIIa has been the most common genotype associated with this outbreak, followed by VGIIb; genotype VGIIc has been the least common genotype and has been isolated only from patients in the United States Pacific Northwest but not from patients in Canada [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3\" class=\"abstract_t\">3</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other molecular types have been documented to cause disease in other regions of the United States, including VGI, non-outbreak VGII types, and VGIII.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>VGIV is rare outside Africa [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In Asia and Mexico, there is a broad distribution of genotypes (<a href=\"image.htm?imageKey=ID%2F90024\" class=\"graphic graphic_table graphicRef90024 \">table 1</a>).</p><p/><p>Whether the different genotypes affect the site, severity, or outcomes of <em>C. gattii</em> infection remains uncertain. There appear to be differences in <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> susceptibility according to molecular type. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment#H15977819\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Treatment&quot;, section on 'Antifungal susceptibilities'</a>.)</p><p class=\"headingAnchor\" id=\"H3960142\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The epidemiology of <em>C. gattii</em> infection is well described in areas endemic for the organism, such as Australia [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/1,23-25\" class=\"abstract_t\">1,23-25</a>], and increasingly in other regions as well. However, many medical centers do not routinely identify cryptococcal isolates to the species level, instead reporting all <em>Cryptococcus</em> spp isolates as <em>C. neoformans</em>. Only after recognition of the North American outbreak (beginning in 1999) and the consequent increased interest in species distinction has the complexity of the epidemiology been appreciated.</p><p class=\"headingAnchor\" id=\"H526557291\"><span class=\"h2\">Geographic distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Australia and Papua New Guinea have long been known to be sites of <em>C. gattii</em> endemic disease. Although <em>C. gattii</em> was formerly thought to be geographically restricted to tropical and subtropical regions, an outbreak in the Pacific Northwest of North America has changed our understanding of the epidemiology of <em>C. gattii</em> infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,16\" class=\"abstract_t\">3,16</a>].</p><p>The emergence of clusters of cryptococcosis due to <em>C. gattii</em> in British Columbia, Canada, in 1999, with subsequent clusters documented in the United States Pacific Northwest, has highlighted the ability of this species to exploit new climatic environments and has expanded our knowledge of the epidemiology and clinical manifestations in the outbreak setting [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/26-33\" class=\"abstract_t\">26-33</a>]. This outbreak was first detected on Vancouver Island in British Columbia, Canada, in 1999 [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,34-36\" class=\"abstract_t\">19,34-36</a>]. Between 1999 and 2007, 218 individuals in British Columbia were found to have <em>C. gattii </em>infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/27\" class=\"abstract_t\">27</a>], and cases continue to occur [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/37\" class=\"abstract_t\">37</a>]. The rate of disease in British Columbia is 0.3 to 0.5 cases per 100,000 population [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/37\" class=\"abstract_t\">37</a>]. Since 2004, over 90 infections have been detected in the United States Pacific Northwest, particularly in Washington and Oregon [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Studies have demonstrated that <em>C. gattii</em> causes sporadic disease in multiple regions of North America, including not only the Pacific Northwest but also California, Idaho, Hawaii, and multiple states on the East Coast (eg, Georgia, Rhode Island, Florida) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/31,38,39\" class=\"abstract_t\">31,38,39</a>]. Sporadic cases have also been detected in temperate regions of Europe [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/40-42\" class=\"abstract_t\">40-42</a>], as well as in Asia, Africa, Mexico, and South America [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,43\" class=\"abstract_t\">3,43</a>]. Although the epidemiology is not well understood, it is becoming better defined as the relevance of species distinction has been appreciated. As noted above, the distribution of <em>C. gattii</em> genotypes varies by geographic region. (See <a href=\"#H3960135\" class=\"local\">'Molecular types'</a> above.)</p><p class=\"headingAnchor\" id=\"H43972912\"><span class=\"h2\">Environmental exposure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Isolates of <em>C. gattii</em> have been found in the environment most commonly in tropical and subtropical areas, such as Australia, Hawaii, Brazil, Southeast Asia, and Central and sub-Saharan Africa [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/44,45\" class=\"abstract_t\">44,45</a>], and in temperate areas such as the Pacific Northwest region of Canada and the United States [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,36\" class=\"abstract_t\">19,36</a>].</p><p>Historically, <em>C. gattii</em> infection has been associated with exposure to certain trees. In particular, an environmental link with two species of Australian eucalypts (or red gum), <em>Eucalyptus camaldulensis</em> and <em>Eucalyptus tereticornis,</em> was first reported in the 1990s [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/46,47\" class=\"abstract_t\">46,47</a>]. The concentration of <em>E. camaldulensis</em> along water courses and the association of rural-dwelling Aborigines with these trees are thought to explain the high prevalence of infection in this population, although host genetic factors in Aborigines and the non-Aboriginal population have not been studied. This link was subsequently confirmed by clinical and molecular epidemiologic studies [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/25,48\" class=\"abstract_t\">25,48</a>] and the association of <em>C. gattii </em>infection with residence or work in a rural or semi-rural domicile has been maintained [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/49\" class=\"abstract_t\">49</a>].</p><p><em>C. gattii</em> has also been isolated from eucalypts in countries with small numbers of human cases, including some parts of the United States, Brazil, and Italy [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/41,47,50\" class=\"abstract_t\">41,47,50</a>]. Cases of <em>C. gattii</em> also occur in regions where eucalypts are not found, such as Malaysia, South America, the Mediterranean basin, and the &quot;Top End&quot; of the northern territory of Australia [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,18,51,52\" class=\"abstract_t\">3,18,51,52</a>]. </p><p>In addition to eucalypts, trees native to Vancouver Island in British Columbia, Canada, have been implicated as an environmental niche for <em>C. gattii</em>; such trees include the Douglas fir, coastal western hemlock, alder, Garry oak, grand fir, and cedar [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3,19\" class=\"abstract_t\">3,19</a>]. In the greater Los Angeles area in the United States, <em>C. gattii</em> has been found in association with trees and soil debris with recovery from the Canary Island pine and American sweetgum, among other species [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/53\" class=\"abstract_t\">53</a>]. In other areas of the United States, <em>C. gattii</em> has also been isolated from soil [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3\" class=\"abstract_t\">3</a>].</p><p>In contrast with the cases in Australia, of which a large proportion occurred in rural areas, cases from British Columbia, Canada, have occurred predominantly in urban and suburban communities [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/16\" class=\"abstract_t\">16</a>]. Many patients in North America have had no apparent exposures other than residing or visiting areas of endemicity.</p><p class=\"headingAnchor\" id=\"H3960149\"><span class=\"h2\">Hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Species-specific differences in the epidemiology of cryptococcosis are well defined and are largely, but not solely, due to differences in host immune status [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Unlike <em>C. neoformans</em>, which typically causes disease in patients with compromised cell-mediated immunity, most cases of <em>C. gattii</em> have been detected in persons with apparently normal immune systems [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/23-25\" class=\"abstract_t\">23-25</a>]. However, it has been hypothesized that some patients with <em>C. gattii</em> infection may have subclinical defects in immunity [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/54\" class=\"abstract_t\">54</a>]. In case series of <em>C. gattii</em> in endemic regions, including Australia, 72 to 100 percent of patients have been immunocompetent [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/24,49,55,56\" class=\"abstract_t\">24,49,55,56</a>]. The majority of patients affected by the Pacific Northwest outbreak in North America have not had medical conditions or therapies classically associated with immunocompromise and have had pulmonary involvement [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,33,35\" class=\"abstract_t\">19,33,35</a>]. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H12417182\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p>However, as <em>C. gattii</em> infection has been studied more intensely, a change in the understanding of the epidemiology has become apparent, with cases of <em>C. gattii</em> meningoencephalitis reported in patients with human immunodeficiency virus (HIV) infection, solid organ transplantation, and other causes of immunodeficiency, as illustrated by the following studies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although <em>C. gattii</em> commonly affects people without apparent immunocompromise, up to 50 percent of patients in some studies [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/31,57\" class=\"abstract_t\">31,57</a>] but not others [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,33,35\" class=\"abstract_t\">19,33,35</a>], from the Pacific Northwest of North America have been immunocompromised. During the outbreak in British Columbia, <em>C. gattii</em> patients were more likely than the general population to be infected with HIV [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/57\" class=\"abstract_t\">57</a>] and, in the United States Pacific Northwest case clusters, 4 of 59 patients (5 percent) were HIV positive [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/31\" class=\"abstract_t\">31</a>]. It is important to note that only subsets of isolates were identified to the species level in most of these studies; thus, our understanding of the impact of <em>C. gattii</em> in HIV-infected individuals remains incomplete.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although population-based studies in Australia and the Gauteng province of South Africa have reported that only 2 percent of cases of HIV-associated cryptococcal meningoencephalitis are ascribed to <em>C. gattii</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/21,25,45\" class=\"abstract_t\">21,25,45</a>], a retrospective study demonstrated a higher prevalence of <em>C. gattii</em> (12.3 percent) as a cause of cryptococcal disease in HIV-infected patients in southern California [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/58\" class=\"abstract_t\">58</a>]. In the outbreak in British Columbia, 4.5 percent of all patients had underlying HIV infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p>In addition to HIV infection, other immunosuppressive conditions that appear to increase the risk for <em>C. gattii </em>disease include organ transplantation, various malignancies, and receipt of glucocorticoids [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/31,49,57,59\" class=\"abstract_t\">31,49,57,59</a>]. Idiopathic CD4+ lymphopenia in the absence of HIV infection, a known risk factor for cryptococcosis due to <em>C. neoformans</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/60,61\" class=\"abstract_t\">60,61</a>], has also been associated with <em>C. gattii</em> infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/49\" class=\"abstract_t\">49</a>].</p><p>Other, more subtle host factors may also increase the risk for <em>C. gattii</em> infection. A proportion of patients with this infection in North America had a history of chronic lung disease. Changes in lung function associated with smoking may contribute to this risk since, in the British Columbia outbreak, more patients had underlying lung disease and were current smokers than was the case in the general population [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H3960163\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. gattii </em>infection is typically acquired by inhalation from the environment, although direct inoculation into the skin has also been reported [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/1,62\" class=\"abstract_t\">1,62</a>]. Both yeast cells and basidiospores probably cause infection since, in nature, <em>C. gattii </em>reproduces both asexually (by budding) and sexually.</p><p>Studies of the pathogenesis of <em>C. gattii </em>infection are limited. In animal models, the outcome of infection<em> </em>is determined by a complex set of interacting pathogen and host factors; these include inoculum size, the cryptococcal strain, and the innate susceptibility or resistance (genetic background) of the host [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/63-65\" class=\"abstract_t\">63-65</a>]. As an example, in studies of the VGII molecular type that caused the outbreak in British Columbia, Canada, the predominant strain (strain R265) was more virulent in mice than the less common strain (strain R272) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19,66\" class=\"abstract_t\">19,66</a>].</p><p>Unlike <em>C. neoformans</em>, <em>C. gattii</em> infection typically causes infection in immunocompetent hosts and is more likely than <em>C. neoformans</em> to cause cryptococcomas of the brain <span class=\"nowrap\">and/or</span> lungs (see <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H211625782\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Comparison of C. gattii and C. neoformans infection'</a>). Although the reasons why cryptococcomas are larger and more common with <em>C. gattii</em> infection remain poorly understood, there are increasing data that the immune response to infection among immunocompetent hosts plays a role. In one study, the cytokine profile of peripheral blood mononuclear cells of healthy individuals was evaluated after in vitro stimulation with heat-killed <em>Cryptococcus</em> isolates [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/67\" class=\"abstract_t\">67</a>]. Isolates of <em>C. gattii</em> induced higher concentrations of the proinflammatory cytokines, interleukin (IL)-1-beta, tumor necrosis factor-alpha, and IL-6 and the T helper <span class=\"nowrap\">17/22</span> cytokines, IL-17 and IL-22, compared with <em>C. neoformans</em>. Toll-like receptor (TLR)-4 and TLR-9, but not TLR-2, also contributed to the host's cytokine response to <em>C. gattii</em>.</p><p>More recently, it was reported that anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies were detected in plasma derived from immunocompetent patients with <em>C. gattii</em> infection but not in the plasma of patients infected with <em>C. neoformans</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/68\" class=\"abstract_t\">68</a>].</p><p class=\"headingAnchor\" id=\"H3960170\"><span class=\"h2\">Virulence determinants</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>C. gattii </em>has similar virulence characteristics as <em>C. neoformans </em>[<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/8\" class=\"abstract_t\">8</a>]<em>. </em>These<em> </em>include the polysaccharide capsule (important in evasion and suppression of the host immune response), the ability to grow at 37&deg;C, production of melanin (via laccase activity), which functions as an oxidative stress protectant, the invasins, phospholipase B (Plb1) and urease, and the antioxidant, superoxide dismutase (SODp1) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/69\" class=\"abstract_t\">69</a>]. In animals with <em>C. neoformans </em>infection, Plb1 and laccase are essential for egress of cryptococci from the lung and dissemination to the central nervous system (CNS) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/70,71\" class=\"abstract_t\">70,71</a>], whereas Plb1 and urease are required for cryptococci<em> </em>to cross the blood-brain barrier [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/71,72\" class=\"abstract_t\">71,72</a>].</p><p class=\"headingAnchor\" id=\"H3960177\"><span class=\"h2\">Neurologic disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>To cause neurologic disease, cryptococci must traverse the lung, disseminate, and cross the blood-brain barrier. In <em>C. neoformans </em>models, cryptococci are transported in the blood in mononuclear phagocytes and as free cells [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/71,72\" class=\"abstract_t\">71,72</a>]. There is also evidence for transendothelial cell transport of free cryptococci<em> </em>and paracellular transport within the phagolysosome of mononuclear phagocytes (the Trojan horse mechanism) [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/73\" class=\"abstract_t\">73</a>]. Cryptococci can be expelled from macrophage phagolysosomes without loss of viability [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/74,75\" class=\"abstract_t\">74,75</a>]. Cryptococci<em> </em>transported within mononuclear phagocytes in blood could therefore be released in cerebral microvessels and cross the blood-brain barrier as free cells. In HIV-associated cryptococcal<em> </em>meningoencephalitis, HIV infection of macrophages facilitates their translocation into the CNS [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/76\" class=\"abstract_t\">76</a>].</p><p>Whether <em>C. gattii</em> differs from <em>C. neoformans</em> in its ability to cause CNS disease is unclear. Among immunocompetent hosts, isolated CNS disease with <em>C. gattii</em>, or CNS plus pulmonary disease, is more common in endemic areas such as Australia, whereas in the outbreak setting in British Columbia, Canada, pulmonary disease is more common [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/27\" class=\"abstract_t\">27</a>].</p><p>In rats with <em>C. gattii </em>genotype VGII infection, VGIIa and VGIIb strains from the British Columbia, Canada, outbreak caused fatal infection confined to the lung, whereas VGIIa strains from Colombia and Australia caused dissemination to the CNS [<a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/77\" class=\"abstract_t\">77</a>].</p><p class=\"headingAnchor\" id=\"H3960184\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Cryptococcus gattii</em> is an important fungal pathogen that is endemic in the tropics and subtropics and that has also caused an outbreak that is ongoing in British Columbia, Canada, and the United States Pacific Northwest. <em>C. gattii</em> is genetically and biochemically distinct from <em>Cryptococcus neoformans</em>. (See <a href=\"#H3960121\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Information about the epidemiology and clinical syndromes caused by <em>C. gattii</em> in nonendemic regions is relatively limited due to the failure of many microbiology laboratories to distinguish between <em>C. neoformans</em> and <em>C. gattii</em>. (See <a href=\"#H3960142\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are at least four molecular types or genotypes of <em>C. gattii</em>, VGI to VGIV, each containing subtypes. Data from studies of molecular types of clinical and environmental strains indicate that genotype distribution and frequency vary in different geographic regions (<a href=\"image.htm?imageKey=ID%2F90024\" class=\"graphic graphic_table graphicRef90024 \">table 1</a>). The reasons for this are unknown but may relate to preferred ecologic niches for different genotypes. (See <a href=\"#H3960135\" class=\"local\">'Molecular types'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Australia and Papua New Guinea have long been known to be sites of <em>C. gattii</em> endemic disease. Although <em>C. gattii</em> was formerly thought to be geographically restricted to tropical and subtropical regions, an outbreak that began in Vancouver Island, Canada, in 1999 and that has spread to the United States Pacific Northwest, and emergence of cases in Europe, has changed our understanding of the epidemiology of <em>C. gattii</em> infection. (See <a href=\"#H526557291\" class=\"local\">'Geographic distribution'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The primary difference in host distribution between <em>C. gattii</em> and <em>C. neoformans</em> is that, at least in regions endemic for <em>C. gattii</em>, this species to a large extent causes infection in people with no apparent immunocompromise, although it has been hypothesized that some patients may have subclinical defects in immunity. <em>C. gattii </em>has also been detected in patients with human immunodeficiency virus (HIV) infection, solid organ transplantation, and other causes of immunodeficiency. (See <a href=\"#H3960149\" class=\"local\">'Hosts'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The outcome of infection<em> </em>is determined by a complex set of interacting pathogen and host factors, including inoculum size, the cryptococcal strain, and the innate susceptibility or resistance of the host. (See <a href=\"#H3960163\" class=\"local\">'Pathogenesis'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/1\" class=\"nounderline abstract_t\">Sorrell TC. Cryptococcus neoformans variety gattii. Med Mycol 2001; 39:155.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/2\" class=\"nounderline abstract_t\">Chaturvedi V, Chaturvedi S. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol 2011; 19:564.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/3\" class=\"nounderline abstract_t\">Harris J, Lockhart S, Chiller T. Cryptococcus gattii: where do we go from here? Med Mycol 2012; 50:113.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/4\" class=\"nounderline abstract_t\">Gatti F, Eeckels R. An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin 1894. I. Description of the disease and of the strain. Ann Soc Belges Med Trop Parasitol Mycol 1970; 50:689.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/5\" class=\"nounderline abstract_t\">Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetiadae). Taxon 2002; 51:804.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/6\" class=\"nounderline abstract_t\">Sharpton TJ, Neafsey DE, Galagan JE, Taylor JW. Mechanisms of intron gain and loss in Cryptococcus. Genome Biol 2008; 9:R24.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/7\" class=\"nounderline abstract_t\">Bovers M, Hagen F, Kuramae EE, et al. AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis 2008; 14:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/8\" class=\"nounderline abstract_t\">Chen SC, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev 2014; 27:980.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/9\" class=\"nounderline abstract_t\">Meyer W. Cryptococcus gattii in the Age of Whole-Genome Sequencing. MBio 2015; 6:e01761.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/10\" class=\"nounderline abstract_t\">Meyer W, Aanensen DM, Boekhout T, et al. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 2009; 47:561.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/11\" class=\"nounderline abstract_t\">Bovers M, Hagen F, Kuramae EE, Boekhout T. Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. Fungal Genet Biol 2008; 45:400.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/12\" class=\"nounderline abstract_t\">Sidrim JJ, Costa AK, Cordeiro RA, et al. Molecular methods for the diagnosis and characterization of Cryptococcus: a review. Can J Microbiol 2010; 56:445.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/13\" class=\"nounderline abstract_t\">Hagen F, Khayhan K, Theelen B, et al. Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol 2015; 78:16.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/14\" class=\"nounderline abstract_t\">Kwon-Chung KJ, Bennett JE, Wickes BL, et al. The Case for Adopting the &quot;Species Complex&quot; Nomenclature for the Etiologic Agents of Cryptococcosis. mSphere 2017; 2.</a></li><li class=\"breakAll\">Meyer W, Gilgado F, Ngamskulrungroj P, et al. Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In: Cryptococcus: from pathogen to model yeast, Heitman J, Kozel TR, Kwon-Chung J, Perfect J, Casadevall A (Eds) (Eds), ASM Press, Washington DC 2011. p.327.</li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/16\" class=\"nounderline abstract_t\">Byrnes EJ 3rd, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect 2011; 13:895.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/17\" class=\"nounderline abstract_t\">Campbell LT, Fraser JA, Nichols CB, et al. Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryot Cell 2005; 4:1410.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/18\" class=\"nounderline abstract_t\">Chen SC, Currie BJ, Campbell HM, et al. Cryptococcus neoformans var. gattii infection in northern Australia: existence of an environmental source other than known host eucalypts. Trans R Soc Trop Med Hyg 1997; 91:547.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/19\" class=\"nounderline abstract_t\">Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 2004; 101:17258.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/20\" class=\"nounderline abstract_t\">Byrnes EJ 3rd, Bildfell RJ, Frank SA, et al. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis 2009; 199:1081.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/21\" class=\"nounderline abstract_t\">Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 2005; 192:888.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/22\" class=\"nounderline abstract_t\">Nyazika TK, Hagen F, Meis JF, Robertson VJ. Cryptococcus tetragattii as a major cause of cryptococcal meningitis among HIV-infected individuals in Harare, Zimbabwe. J Infect 2016; 72:745.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/23\" class=\"nounderline abstract_t\">Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/24\" class=\"nounderline abstract_t\">Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21:28.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/25\" class=\"nounderline abstract_t\">Chen S, Sorrell T, Nimmo G, et al. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 2000; 31:499.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/26\" class=\"nounderline abstract_t\">MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13:42.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/27\" class=\"nounderline abstract_t\">Galanis E, Macdougall L, Kidd S, et al. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16:251.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/28\" class=\"nounderline abstract_t\">Datta K, Bartlett KH, Baer R, et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg Infect Dis 2009; 15:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/29\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Emergence of Cryptococcus gattii-- Pacific Northwest, 2004-2010. MMWR Morb Mortal Wkly Rep 2010; 59:865.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/30\" class=\"nounderline abstract_t\">Marr KA. Cryptococcus gattii as an important fungal pathogen of western North America. Expert Rev Anti Infect Ther 2012; 10:637.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/31\" class=\"nounderline abstract_t\">Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/32\" class=\"nounderline abstract_t\">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/33\" class=\"nounderline abstract_t\">Phillips P, Galanis E, MacDougall L, et al. Longitudinal clinical findings and outcome among patients with Cryptococcus gattii infection in British Columbia. Clin Infect Dis 2015; 60:1368.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/34\" class=\"nounderline abstract_t\">Stephen C, Lester S, Black W, et al. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can Vet J 2002; 43:792.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/35\" class=\"nounderline abstract_t\">Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004; 53:935.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/36\" class=\"nounderline abstract_t\">Bartlett KH, Kidd SE, Kronstad JW. The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr Infect Dis Rep 2008; 10:58.</a></li><li class=\"breakAll\">BC Centre for Disease Control. 2015 British Columbia annual summary of reportable diseases. http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Statistics%20and%20Reports/Epid/Annual%20Reports/2015CDAnnualReportFinal.pdf (Accessed on May 17, 2017).</li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/38\" class=\"nounderline abstract_t\">Kunadharaju R, Choe U, Harris JR, et al. Cryptococcus gattii, Florida, USA, 2011. Emerg Infect Dis 2013; 19:519.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/39\" class=\"nounderline abstract_t\">Harris JR, Lockhart SR, Sondermeyer G, et al. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg Infect Dis 2013; 19:1620.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/40\" class=\"nounderline abstract_t\">Chowdhary A, Randhawa HS, Boekhout T, et al. Temperate climate niche for Cryptococcus gattii in Northern Europe. Emerg Infect Dis 2012; 18:172.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/41\" class=\"nounderline abstract_t\">Montagna MT, Viviani MA, Pulito A. Cryptococcus neoformans var. gattii in Italy. Environmental investigation related to an autochtonous clinical case in Apulia. J Mycol Med 1997; 7:93.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/42\" class=\"nounderline abstract_t\">Hagen F, Hare Jensen R, Meis JF, Arendrup MC. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark. Mycoses 2016; 59:576.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/43\" class=\"nounderline abstract_t\">Herkert PF, Hagen F, de Oliveira Salvador GL, et al. Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis 2016; 35:1803.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/44\" class=\"nounderline abstract_t\">Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984; 120:123.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/45\" class=\"nounderline abstract_t\">Morgan J, McCarthy KM, Gould S, et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin Infect Dis 2006; 43:1077.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/46\" class=\"nounderline abstract_t\">Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28:1642.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/47\" class=\"nounderline abstract_t\">Ellis D, Pfeiffer T. Cryptococcosis and the ecology of Cryptococcus neoformans. Jpn J Med Mycol 1995; 35:111.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/48\" class=\"nounderline abstract_t\">Sorrell TC, Chen SC, Ruma P, et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 1996; 34:1253.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/49\" class=\"nounderline abstract_t\">Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55:789.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/50\" class=\"nounderline abstract_t\">Montenegro H, Paula CR. Environmental isolation of Cryptococcus neoformans var. gattii and C. neoformans var. neoformans in the city of S&atilde;o Paulo, Brazil. Med Mycol 2000; 38:385.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/51\" class=\"nounderline abstract_t\">Keah KC, Parameswari S, Cheong YM. Serotypes of clinical isolates of Cryptococcus neoformans in Malaysia. Trop Biomed 1994; 11:205.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/52\" class=\"nounderline abstract_t\">Cogliati M, D'Amicis R, Zani A, et al. Environmental distribution of Cryptococcus neoformans and C. gattii around the Mediterranean basin. FEMS Yeast Res 2016; 16.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/53\" class=\"nounderline abstract_t\">Springer DJ, Billmyre RB, Filler EE, et al. Cryptococcus gattii VGIII isolates causing infections in HIV/AIDS patients in Southern California: identification of the local environmental source as arboreal. PLoS Pathog 2014; 10:e1004285.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/54\" class=\"nounderline abstract_t\">Marr KA, Datta K, Pirofski LA, Barnes R. Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin Infect Dis 2012; 54:153.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/55\" class=\"nounderline abstract_t\">Lalloo D, Fisher D, Naraqi S, et al. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. Q J Med 1994; 87:343.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/56\" class=\"nounderline abstract_t\">Jenney A, Pandithage K, Fisher DA, Currie BJ. Cryptococcus infection in tropical Australia. J Clin Microbiol 2004; 42:3865.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/57\" class=\"nounderline abstract_t\">MacDougall L, Fyfe M, Romney M, et al. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 2011; 17:193.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/58\" class=\"nounderline abstract_t\">Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. Cryptococcus gattii in AIDS patients, southern California. Emerg Infect Dis 2005; 11:1686.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/59\" class=\"nounderline abstract_t\">Forrest GN, Bhalla P, DeBess EE, et al. Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases. Transpl Infect Dis 2015; 17:467.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/60\" class=\"nounderline abstract_t\">Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007; 86:78.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/61\" class=\"nounderline abstract_t\">Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004; 39:e83.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/62\" class=\"nounderline abstract_t\">Hamann ID, Gillespie RJ, Ferguson JK. Primary cryptococcal cellulitis caused by Cryptococcus neoformans var. gattii in an immunocompetent host. Australas J Dermatol 1997; 38:29.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/63\" class=\"nounderline abstract_t\">Chen SC, Muller M, Zhou JZ, et al. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 1997; 175:414.</a></li><li class=\"breakAll\">Casadevall A, Perfect JR. Animal models and veterinary aspects of cryptococcosis. In: Cryptococcosis, ASM Press, Washington DC 1998. p.325.</li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/65\" class=\"nounderline abstract_t\">Leopold Wager CM, Hole CR, Wozniak KL, Wormley FL Jr. Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome. Front Microbiol 2016; 7:105.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/66\" class=\"nounderline abstract_t\">Ngamskulrungroj P, Price J, Sorrell T, et al. Cryptococcus gattii virulence composite: candidate genes revealed by microarray analysis of high and less virulent Vancouver island outbreak strains. PLoS One 2011; 6:e16076.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/67\" class=\"nounderline abstract_t\">Schoffelen T, Illnait-Zaragozi MT, Joosten LA, et al. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS One 2013; 8:e55579.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/68\" class=\"nounderline abstract_t\">Saijo T, Chen J, Chen SC, et al. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. MBio 2014; 5:e00912.</a></li><li class=\"breakAll\">Chaturvedi S, Chaturvedi V. Virulence mechanisms of Cryptococcus gattii: Convergence and divergence. In: Cryptococcus: From Human Pathogen to Model Yeast, Heitman J, Kozel T, Kwon-Chung KJ, et al (Eds), ASM Press, Washington, DC 2011. p.189.</li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/70\" class=\"nounderline abstract_t\">Noverr MC, Williamson PR, Fajardo RS, Huffnagle GB. CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun 2004; 72:1693.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/71\" class=\"nounderline abstract_t\">Santangelo R, Zoellner H, Sorrell T, et al. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect Immun 2004; 72:2229.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/72\" class=\"nounderline abstract_t\">Shi M, Li SS, Zheng C, et al. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 2010; 120:1683.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/73\" class=\"nounderline abstract_t\">Charlier C, Nielsen K, Daou S, et al. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun 2009; 77:120.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/74\" class=\"nounderline abstract_t\">Ma H, Croudace JE, Lammas DA, May RC. Expulsion of live pathogenic yeast by macrophages. Curr Biol 2006; 16:2156.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/75\" class=\"nounderline abstract_t\">Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, et al. Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions. Infect Immun 2010; 78:1601.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/76\" class=\"nounderline abstract_t\">Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol 2008; 82:7591.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis/abstract/77\" class=\"nounderline abstract_t\">Krockenberger MB, Malik R, Ngamskulrungroj P, et al. Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model. Mycopathologia 2010; 170:315.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 16624 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H3960184\"><span>SUMMARY</span></a></li><li><a href=\"#H3960121\" id=\"outline-link-H3960121\">INTRODUCTION</a></li><li><a href=\"#H3960128\" id=\"outline-link-H3960128\">MICROBIOLOGY</a><ul><li><a href=\"#H3960135\" id=\"outline-link-H3960135\">Molecular types</a></li></ul></li><li><a href=\"#H3960142\" id=\"outline-link-H3960142\">EPIDEMIOLOGY</a><ul><li><a href=\"#H526557291\" id=\"outline-link-H526557291\">Geographic distribution</a></li><li><a href=\"#H43972912\" id=\"outline-link-H43972912\">Environmental exposure</a></li><li><a href=\"#H3960149\" id=\"outline-link-H3960149\">Hosts</a></li></ul></li><li><a href=\"#H3960163\" id=\"outline-link-H3960163\">PATHOGENESIS</a><ul><li><a href=\"#H3960170\" id=\"outline-link-H3960170\">Virulence determinants</a></li><li><a href=\"#H3960177\" id=\"outline-link-H3960177\">Neurologic disease</a></li></ul></li><li><a href=\"#H3960184\" id=\"outline-link-H3960184\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/16624|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/90024\" class=\"graphic graphic_table\">- Cryptococcus gattii genotypes</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Cryptococcus gattii infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment\" class=\"medical medical_review\">Cryptococcus gattii infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-and-epidemiology-of-cryptococcus-neoformans-infection\" class=\"medical medical_review\">Microbiology and epidemiology of Cryptococcus neoformans infection</a></li></ul></div></div>","javascript":null}